Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinit...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelaia, Corrado, Calabrese, Cecilia, Terracciano, Rosa, de Blasio, Francesco, Vatrella, Alessandro, Pelaia, Girolamo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236630/
https://www.ncbi.nlm.nih.gov/pubmed/30400762
http://dx.doi.org/10.1177/1753466618810192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236630/
https://www.ncbi.nlm.nih.gov/pubmed/30400762
http://dx.doi.org/10.1177/1753466618810192

Ejemplares similares